10 Feb 2026 CHF0.0012 ObsEva (OBSN.SW) SIX Pre-Market Most Active: 2.35M shares signal volatility

OBSN.SW stock opened in the SIX pre-market at CHF0.0012, down 76.92% from the previous close. Trading is heavy with 2,351,202 shares changing hands versus an average of 675,842, making ObsEva S.A. one of the most active names on the board today. Intraday swings reflect a sharp sell-off from the open CHF0.0050 and a year high gap at CHF0.085. We flag this as a high-volatility biotech move tied to liquidity and pipeline news, and we explain key metrics and the short-term outlook below.

OBSN.SW stock market snapshot

ObsEva S.A. (OBSN.SW) trades on the SIX exchange in Switzerland. Current price is CHF0.0012. Market cap stands near CHF140,612. Day range is CHF0.0012–CHF0.0058. Average 50-day price is CHF0.01469 and 200-day price is CHF0.04393. The Swiss Healthcare sector is up 1.96% today while ObsEva is sharply lower, highlighting company-specific pressure.

Intraday drivers and volume for OBSN.SW stock

Volume is the main story. 2,351,202 shares traded, a 3.48x relative volume spike. The stock opened at CHF0.0050 and collapsed to CHF0.0012 on heavy selling. Low free float and 117,177,000 outstanding shares amplify moves. High volume with a low price signals speculative exits and squeezes. Watch for continued volatility into the SIX session.

OBSN.SW stock financials and valuation

Latest reported EPS is -0.29 and the reported PE is deeply negative. Price-to-sales is 0.01 and price-to-book is 0.017. Cash per share is CHF0.0915 and current ratio is 2.23, showing short-term liquidity. Revenue per share sits at 0.21. These ratios show a heavily distressed market value versus balance-sheet metrics. Investors should note enterprise value anomalies due to the tiny market cap.

Meyka AI rates OBSN.SW with a score out of 100

Meyka AI rates OBSN.SW with a score of 62.62 out of 100 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. These ratings are not guarantees and do not constitute financial advice. For full company materials see the ObsEva site source and our stock page Meyka OBSN.SW.

Price targets, forecast and OBSN.SW stock outlook

No consensus analyst price target exists. Meyka AI’s forecast model projects a base near CHF0.0050, a conservative downside of CHF0.0008, and a bullish scenario to CHF0.0200. Versus the current CHF0.0012, the base projection implies +316.67% upside. Forecasts are model-based projections and not guarantees. We expect headlines and liquidity shifts to drive short-term moves, not fundamentals.

Risks, catalysts and trading strategy for OBSN.SW stock

Key risks include further dilution, clinical setbacks, and extremely low liquidity. Catalysts that could change the picture include trial updates, licensing news, or a placement. For most traders, the stock suits speculative, short-term strategies only. Long-term investors should await clearer clinical milestones and funding events before scaling positions.

Final Thoughts

OBSN.SW stock is a high-risk, high-volatility biotech name trading on the SIX at CHF0.0012 pre-market. The large intraday volume of 2,351,202 shares and a -76.92% move show market participants reacting to liquidity and company news rather than fresh fundamental data. Meyka AI’s forecast model projects a base price near CHF0.0050, implying +316.67% from the current price. We provide this forecast as a model-based projection, not a guarantee. Our proprietary grade is 62.62 (B, HOLD), reflecting mixed sector metrics and fragile financials. Traders should prioritise risk controls, size positions small, and monitor cash runway, EPS, and any pipeline releases. For more company filings consult ObsEva’s site source. Meyka AI is the AI-powered market analysis platform that provides real-time signals and grading, but readers must carry out their own research and risk assessment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.